|
1
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumors. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Creighton CJ: The molecular profile of
luminal B breast cancer. Biologics. 6:289–297. 2012.PubMed/NCBI
|
|
4
|
Katzenellenbogen BS and Katzenellenbogen
JA: Estrogen receptor transcription and transactivation: Estrogen
receptor alpha and estrogen receptor beta: Regulation by selective
estrogen receptor modulators and importance in breast cancer.
Breast Cancer Res. 2:335–344. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burns KA and Korach KS: Estrogen receptors
and human disease: An update. Arch Toxicol. 86:1491–1504. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Higa GM and Fell RG: Sex hormone receptor
repertoire in breast cancer. Int J Breast Cancer. 2013:2840362013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shanle EK and Xu W: Selectively targeting
estrogen receptors for cancer treatment. Adv Drug Deliver Rev.
62:1265–1276. 2010. View Article : Google Scholar
|
|
9
|
Britton DJ, Hutcheson IR, Knowlden JM,
Barrow D, Giles M, McClelland RA, Gee JMW and Nicholson RI:
Bidirectional cross talk between ERalpha and EGFR signalling
pathways regulates tamoxifen-resistant growth. Breast Cancer Res
Treat. 96:131–146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeselsohn R, Buchwalter G, De Angelis C,
Brown M and Schiff R: ESR1 mutations-a mechanism for acquired
endocrine resistance in breast cancer. Nat Rev Clin Oncol.
12:573–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morandi A, Martin L, Gao Q, Pancholi S,
Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I and
Isacke CM: GDNF-RET signaling in ER-positive breast cancers is a
key determinant of response and resistance to aromatase inhibitors.
Cancer Res. 73:3783–3795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang P, Bahreini A, Gyanchandani R, Lucas
PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE,
Berg A, Hamilton RL, et al: Sensitive detection of mono- and
polyclonal ESR1 mutations in primary tumors, metastatic lesions and
cell free DNA of breast cancer patients. Clin Cancer Res.
22:1130–1137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stathopoulos GP and Trafalis D: High-dose
tamoxifen in breast cancer bone metastasis. J BUON. 18:532–534.
2013.PubMed/NCBI
|
|
15
|
Hendrick A and Subramanian VP: Tamoxifen
and thromboembolism. JAMA. 243:514–515. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Musgrove EA and Sutherland L: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu
S, Kerlikowske K and Ziv E: Clinical and biomarker predictors of
side effects from tamoxifen. Breast Cancer Res Treat.
132:1107–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Castrellon AB: Novel strategies to improve
the endocrine therapy of breast cancer. Oncol Rev. 11:3232017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang
Y, Lai X, Wei Y, Yu S, Zhang J, et al: Metformin enhances
tamoxifen-mediated tumor growth inhibition in ER-positive breast
carcinoma. BMC Cancer. 14:1722014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar BN, Rajput S, Dey KK, Parekh A, Das
S, Mazumdar A and Mandal M: Celecoxib alleviates
tamoxifen-instigated angiogenic effects by ROS-dependent
VEGF/VEGFR2 autocrine signaling. BMC Cancer. 13:2732013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hare SH and Harvey AJ: mTOR function and
therapeutic targeting in breast cancer. Am J Cancer Res. 7:383–404.
2017.PubMed/NCBI
|
|
22
|
Wong SW, Tiong KH, Kong WY, Yue YC, Chua
CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, et al: Rapamycin
synergizes cisplatin sensitivity in basal-like breast cancer cells
through up-regulation of p73. Breast Cancer Res Treat. 128:301–313.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin L, Pancholi S, Farmer I, Guest S,
Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, et
al: Effectiveness and molecular interactions of the clinically
active mTORC1 inhibitor everolimus in combination with tamoxifen or
letrozole in vitro and in vivo. Breast Cancer Res. 14:R1322012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou T and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schindlbeck C, Jeschke U, Schulze S,
Karsten U, Janni W, Rack B, Krajewski S, Sommer H and Friese K:
Prognostic impact of Thomsen-Friedenreich tumor antigen and
disseminated tumor cells in the bone marrow of breast cancer
patients. Breast Cancer Res Treat. 101:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lou P, Li C, Shi L, Xia TS, Zhou W, Wu J,
Zhou X, Li X, Wang Y, Wei JF, et al: RNPC1 enhances progesterone
receptor functions by regulating its mRNA stability in breast
cancer. Oncotarget. 8:16387–16400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi L, Xia T, Wei X, Zhou W, Xue J, Cheng
L, Lou P, Li C, Wang Y, Wei JF, et al: Estrogen receptor (ER) was
regulated by RNPC1 stabilizing mRNA in ER positive breast cancer.
Oncotarget. 6:12264–12278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li XX, Shi L, Zhou XJ, Wu J, Xia TS, Zhou
WB, Sun X, Zhu L, Wei JF and Ding Q: The role of c-Myc-RBM38 loop
in the growth suppression in breast cancer. J Exp Clin Cancer Res.
36:492017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tamoxifen for early breast cancer: An
overview of the randomised trials. Early breast cancer trialists'
collaborative group. Lancet. 351:1451–1467. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davies C, Pan H, Godwin J, Gray R,
Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A,
Bonfill X, et al: Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised
trial. Lancet. 381:805–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Raje N, Kumar S, Hideshima T, Ishitsuka K,
Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi
NC, et al: Combination of the mTOR inhibitor rapamycin and CC-5013
has synergistic activity in multiple myeloma. Blood. 104:4188–4193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget.
1:530–543. 2010.PubMed/NCBI
|
|
35
|
Ellis MJ, Tao Y, Young O, White S, Proia
AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, et al:
Estrogen-independent proliferation is present in estrogen-receptor
HER2-positive primary breast cancer after neoadjuvant letrozole. J
Clin Oncol. 24:3019–3025. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Law JH, Habibi G, Hu K, Masoudi H, Wang
MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al:
Phosphorylated insulin-like growth factor-i/insulin receptor is
present in all breast cancer subtypes and is related to poor
survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Creighton CJ, Fu X, Hennessy BT, Casa AJ,
Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck
SG, et al: Proteomic and transcriptomic profiling reveals a link
between the PI3K pathway and lower estrogen-receptor (ER) levels
and activity in ER+ breast cancer. Breast Cancer Res. 12:R402010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saal LH, Johansson P, Holm K,
Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA,
Malmström P, Memeo L, et al: Poor prognosis in carcinoma is
associated with a gene expression signature of aberrant PTEN tumor
suppressor pathway activity. Proc Natl Acad Sci USA. 104:7564–7569.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gonzalez-Angulo AM, Ferrer-Lozano J,
Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM,
Chen H, Hortobagyi GN, et al: PI3K pathway mutations and PTEN
levels in primary and metastatic breast cancer. Mol Cancer Ther.
10:1093–1101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pérez-Tenorio G, Alkhori L, Olsson B,
Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L and Stål O:
PIK3CA mutations and PTEN loss correlate with similar prognostic
factors and are not mutually exclusive in breast cancer. Clin
Cancer Res. 13:3577–3584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ciruelos Gil EM: Targeting the
PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shirley SH, Rundhaug JE, Tian J,
Cullinan-Ammann N, Lambertz I, Conti CJ and Fuchs-Young R:
Transcriptional regulation of estrogen receptor-alpha by p53 in
human breast cancer cells. Cancer Res. 69:3405–3414. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rosenbluth JM, Mays DJ, Jiang A, Shyr Y
and Pietenpol JA: Differential regulation of the p73 cistrome by
mammalian target of rapamycin reveals transcriptional programs of
mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci
USA. 108:2076–2081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bachelot T, Bourgier C, Cropet C,
Ray-Coquard I, Ferrero J, Freyer G, Abadie-Lacourtoisie S, Eymard
J, Debled M, Spaëth D, et al: Randomized phase II trial of
everolimus in combination with tamoxifen in patients with hormone
receptor-positive, human epidermal growth factor receptor
2-negative metastatic breast cancer with prior exposure to
aromatase inhibitors: A GINECO study. J Clin Oncol. 30:2718–2724.
2012. View Article : Google Scholar : PubMed/NCBI
|
